Anaphylaxis in Patients with Hemophilia

ABSTRACT

Anaphylactic reactions are rare emergencies observed in hemophilia patients. In hemophilia (B) (HB) patients they typically occur coincident with the development of an inhibitor. It is important to be aware of the possibility of such reactions, and the patient's family should be educated at the time of initial diagnosis and discussion. Because these reactions typically occur within the first 10 to 20 treatment courses, the first few infusions should be given in a hospital/clinic setting equipped to manage such emergencies. Obtaining the exact genotype may identify the HB patients at risk for this complication. When immune tolerance induction (ITI) is attempted in patients with HB inhibitors and anaphylaxis, the physician should be vigilant in detecting proteinuria.

KEYWORD

Hemophilia A - hemophilia B - factor concentrates - factor VIII inhibitor - factor IX inhibitor - anaphylaxis - nephrotic syndrome

REFERENCES

• 1 Nuss R, Hedegaard H, Riske B. Medical care of hemophilia.  Haemophilia . 1998;  4 806-811
• 2 Montgomery R R, Gill J C, Scott J P. Hemophilia and von Willebrand disease. In: Nathan DG, Orkin SH, eds. Nathan and Oski's Hematology of Infancy and Childhood, 5th ed Philadelphia, PA: Saunders, 1998: 1631-1659
• 3 Warrier I, Ewenstein B M, Koerper M A. Factor IX inhibitors and anaphylaxis in hemophilia B.  J Pediatr Hematol Oncol . 1997;  19 23-27
• 4 Burman D, Hodson A K, Woods C BS. Acute anaphylaxis, pulmonary oedema, and intravascular haemolysis due to cryoprecipitate.  Arch Dis Child . 1973;  48 483-485
• 5 Clapp R, Green D. Reaction to rapidly infused AHF cryoprecipitate.  N Engl J Med . 1969;  281 329
• 6 Ahrons S, Glavind-Kristensen S, Drachmann O. Severe reactions after cryoprecipitated human factor VIII.  Vox Sang . 1970;  18 182-184
• 7 Eyster M E, Bowman H S, Haverstick J N. Adverse reactions to factor VIII infusions.  Ann Intern Med . 1977;  87 248
• 8 Erskine J G, Davidson J F. Anaphylactic reaction to low-molecular-weight porcine factor VIII concentrates.  Br Med J Clin Res Ed . 1981;  282 2011-2012
• 9 Bove J R. Anaphylactic reaction to purified antihemophilic factor concentrate.  Transfusion . 1988;  28 603
• 10 Shopnick R I, Kazemi M, Brettler D B. Anaphylaxis after treatment with recombinant factor VIII.  Transfusion . 1996;  36 358-361
• 11 Tsuchiya H, Shima M, Yoshioka A. Anaphylactic response to factor VIII preparations in a hemophilic child with an inhibitor of high titre during the tolerance induction.  Eur J Pediatr . 1998;  157 85
• 12 Pernod G, Armari C, Barro C. Anaphylaxis following the use of a plasma-derived immunopurified Monoclate-P, and the recombinant Recombinate and Kogenate factor VIII: A therapeutic challenge.  Haemophilia . 1999;  5 143-144
• 13 Davis H M, Brown S K, Nash D W. Lack of immune response to mouse IgG in hemophilia A patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIII preparation.  Thromb Haemost . 1990;  63 386-391
• 14 Helmer III E R, Alperin J B, Yunginger J W. Anaphylactic reactions following infusion of factor VIII in a patient with classic hemophilia.  Am J Med . 1980;  69 953-957
• 15 Jamieson D M, Stafford C T, Maloney M J. Desensitization to factor VIII in a patient with classic hemophilia and C2 deficiency.  Ann Allergy . 1987;  58 215-220
• 16 Bergamaschini L, Mannucci P M, Federici A B. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: Role of complement and alloantibodies to von Willebrand factor.  J Lab Clin Med . 1995;  125 348-355
• 17 Shakib F, Stanworth D R. Ig4: A possible mediator of anaphylaxis in a haemophiliac patient.  Clin Allergy . 1979;  9 597-603
• 18 Harper J L, Gill J C, Hopp R J. Induction of immune tolerance in a 7-year-old hemophilic with an anaphylactoid inhibitor.  Thromb Haemost . 1995;  74 1039-1041
• 19 Warrier I. Management of hemophilia B patients with inhibitors and anaphylaxis.  Haemophilia . 1998;  4 574-576
• 20 Tengborn L, Hansson S, Fasth A. Anaphylactoid reactions and nephrotic syndrome-a considerable risk during factor IX treatment in patients with hemophilia B and inhibitors: A report on the outcome in two patients.  Haemophilia . 1998;  4 854-859
• 21 Thorland E C, Drost J B, Lusher J M. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: Complete gene deletions confer the highest risk.  Haemophilia . 1999;  5 101-105
• 22 Sawamoto Y, Midori S, Masakuni Y. Measurement of anti-factor IX subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates.  Thromb Res . 1996;  83 279-286
• 23 Dioun A F, Ewenstein B M, Geha R S. IgE-mediated allergy and sensitization to factor IX in hemophilia B.  J Allergy Clin Immunol . 1998;  102 113-117
• 24 Warrier I, Lusher J M. Development of anaphylactic shock in hemophilia B patients with inhibitors.  Blood Coagul Fibrinolysis . 1998;  9 S125-128
• 25 Ewenstein B M, Takemoto C, Warrier I. Nephrotic syndrome as a complication of immune tolerance in hemophilia B.  Blood . 1997;  89 1115-1116
• 26 Constantinescu A R, Weiss L S, Saidi P. Nephrotic syndrome associated with hypocomplementemia in a 4-year-old boy with hemophilia B.  J Pediatr Hematol Oncol . 1997;  19 345-347
• 27 Manucci P M, Tamaro G, Narchi G. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor.  Eur J Haematol . 1987;  39 467-470
• 28 Mannucci P M, Ruggeri Z M, Ciavarella N. Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: Effects on replacement therapy.  Blood . 1981;  57 25-31